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Abstract
Background: Chromosomal translocations are a hallmark of cancer cells and give rise to fusion oncogenes.
To gain insight into the mechanisms governing tumorigenesis, adequate model cell lines are required.
Results: We employ the versatile CRISPR/Cas system to engineer cell lines in which chromosomal
translocations are either generated de novo (CD74-ROS1) or existing translocations are reverted back to the
original configuration (BCR-ABL1). To this end, we co-apply two guide RNAs to artificially generate two
breakpoints and screen for spontaneous fusion events by PCR.
Conclusions: The approach we use is efficient and delivers clones bearing translocationsin a predictable
fashion. Detailed analysis suggests that the clones display no additional undesired alterations, implying that
the approach is robust and precise.
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Background
Chromosome abnormalities are a characteristic feature
of cancer cells. Recurrent chromosome rearrange-
ments, like translocations, are often found in various
tumour types, and there is overwhelming evidence that
they are key drivers of tumorigenesis [1]. Balanced
chromosome translocations produce gene fusions, fre-
quently leading to activation and overexpression of a
gene due to the translocation. The nature of gene
fusions strongly correlates with the tumour type, mak-
ing them very attractive targets for cancer diagnostic
or therapeutic intervention [2].
The first ever identified chromosome translocation
in cancer was the Philadelphia chromosome originat-
ing from a balanced translocation between chromo-
somes 9 and 22 [1]. The Philadelphia chromosome is a
characteristic feature of chronic myelogenous leukemia
and was found in most of patients with this disease [3].
At the molecular level this translocation gives rise to
the BCR-ABL1 fusion, thereby deregulating ABL1
tyrosine kinase activity. As a consequence, down-
stream signalling pathways are activated and malig-
nant transformation of hematopoietic cells is induced
[4]. The BCR-ABL1 gene fusion serves as a clinical
biomarker for diagnostic and a therapeutic target for
several drugs like imatinib, dasatinib, nilotinib and
others [2].
Chromosome rearrangements involving ROS1 gene
have been found in 1–2 % of patients with non-small cell
lung cancers. Several fusion partners are known for
ROS1, among which CD74 is the most common [5]. The
CD74-ROS1 gene fusion is formed as result of a
balanced translocation between chromosomes 5 and 6 in
a way that preserves the tyrosine kinase domain of
ROS1 [5]. As a result of this rearrangements, ROS1
kinase is constitutively active, rendering the CD74-ROS1
gene fusion a potent oncogenic driver [6].
Chromosomal translocations are triggered in vivo by
the simultaneous occurrence of double strand breaks.
To generate such translocations in defined cellular
models, we used CRISPR/Cas technology [7, 8]. Cas9 is
bacterial endonuclease derived from Streptococcus
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pyogenes that can be reprogrammed by short RNAs (so
called guide RNAs) to induce a DNA double-strand
break at any position that is followed by a protospacer
adjacent motif (PAM) (NGG for S. pyogenes Cas9).
Repair of the double-stand break can either occur by
non-homologous end joining or by homology-directed
repair, depending on whether a homology template is
present or not. The CRISPR/Cas system has been used
for genome engineering in a large number of species and
for a wide variety of purposes (for review see [9]). The
technology has also been used to engineer translocations
in cells [10] or in mice [11, 12], but the overall efficiency
by which clones were retrieved was not always apparent
and the resulting cell lines were poorly characterized.
Here, we employed the haploid human cell line
referred to as eHAP [13] as a model system to engineer
or revert chromosomal translocations. We generated the
CD74-ROS1 fusion de novo or reverted the BCR-ABL1
fusion that is naturally present in eHAP cells back to the
wild-type state. Genotyping of hundreds of clones
provides a measure for the overall efficiency of the
process. Individual clones were characterized in great
detail to assess the precision and robustness of the
approach we devised.
Results
To test the feasibility of engineering chromosomal
translocations we attempted to generate the CD74-
ROS1 gene fusion de novo (Fig. 1a). In parallel, we
aimed to revert the existing BCR-ABL1 translocation
back to wild-type state (Fig. 1b).
In both cases, we used a similar approach. We
applied Cas9 together with two guide RNAs, targeting
the two breakpoints that we wished to create (Fig. 1,
Additional file 1: Figure S1). Following enrichment of
transfected cells using transient blasticidin selection,
we isolated single cells by limiting dilution and geno-
typed clones for the presence/absence of the desired
translocation. We screened a total number of 192
clones for CD74-ROS1 and 384 clones for BCR-ABL1
using PCR with primers spanning the newly generated
junctions to identify clones harbouring translocation
(Fig. 2a, Additional file 2: Figure S2 and Additional file 3:
Figure S3). For CD74-ROS1, we recovered 2 clones
(1.04 % targeting efficiency) that were positive for both the
CD74-ROS1 and the reciprocal junction (Fig. 2b). For the
reversion of BCR-ABL1, we identified 3 clones (0.78 % tar-
geting efficiency) displaying the wild-type BCR and ABL1
junctions (Fig. 2b). We also show feasibility of this method
in diploid cell line HEK293T (Fig. 1a and Additional file 4:
Figure S4).
Mutant clones 1G13 (CD74-ROS1) and 4 L20 (BCR-
ABL1 reversion) were selected for further analysis at the
genomic DNA level. PCR analysis indicated that the mutant
clones contained the desired translocation and that this
translocation was absent in parental eHAP cells (Fig. 2c,
Additional file 5: Figure S5). Conversely, the original
sequences (CD74 and ROS1 wild-type or BCR-ABL1 and
ABL1-BCR fusions) were only detectable in the parental
cells, but not in the mutants. This indicates that the trans-
location occurred as expected and that each mutation/
translocation is present at a 100 % allele frequency in the
resulting mutant eHAP cells.
We also assessed whether the CD74-ROS1 transloca-
tion and BCR and ABL1 were detectable at the mRNA
level. Clearly, the fusion of CD74 exon 6 to ROS1 exon
34 was detected by RT-PCR in the clone 1G13. Likewise,
both BCR and ABL1 expression were restored in the
clone 4 L20 (Fig. 3a). Sanger sequencing of the RT-PCR























Fig. 1 Strategy to induce translocations using CRISPR-Cas9. (a) The CD74-ROS1 rearrangement was generated by inducing a translocation between
chromosomes 5 and 6. gRNA3190 and gRNA3188 were used to target wtCas9 nuclease to chromosome 6 and 5 respectively. Primers used for screening
clones are shown. (b) BCR-ABL1 rearrangement was reverted by inducing translocation between chromosome 22 (Philadelphia chromosome) and 9.
gRNA3279 and gRNA3281 were used to target wtCas9 nuclease to chromosome 22 and 9 respectively
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without additional insertions or deletion (Fig. 3b). Given
the fact that the DNA double strand breaks/transloca-
tions occurred in intronic sequences, this was expected.
We used spectral karyotyping [14] and G-band
karyotyping to visualize the engineered translocations
at the chromosomal level and to also assess whether
additional undesired gross rearrangements had
occurred. Spectral karyotyping and G-band staining
revealed that the parental cell line eHAP contained
intact chromosomes 5 and 6 and the reciprocal trans-
location between chromosomes 9 and 22 that give rise
to the Philadelphia chromosome (Fig. 4a). Clone
1G13, which contains the CD74-ROS1 fusion,
acquired a balanced translocation between the long
arms of chromosome 5 and 6 (Fig. 4b, Additional file
6: Figure S6a). Clone 4 L20, in which we reverted the
BCR-ABL1 fusion, displayed intact chromosomes 9
and 22, confirming the reversion of BCR-ABL1 trans-
location at the chromosomal level (Fig. 4c, Additional
file 6: Figure S6b). Importantly, spectral karyotyping
showed that engineered clones did not acquire add-
itional chromosomal rearrangements due to potential
CRISPR/Cas9 off-target activity. Taken together, these
results show that CRIPSR/Cas9 system can be used to
efficiently generate gross chromosomal rearrange-
ments in human cells.
Discussion
Chromosomal translocations underlie a variety of malig-
nancies, yet definitive experimental models are missing.
Here, we use the haploid human cell line eHAP to
generate or revert such translocations. The method we
use is efficient and works with surgical precision both in
haploid and diploid backgrounds. By combining two
guide RNAs, we introduce two simultaneous double
strand breaks that get spontaneously joined by the
endogenous DNA damage repair machinery. We specu-
late that Cas9 may serve as a bridging function as it is
needed to generate both breaks. Consequently, the spon-
taneous fusion rate may be enhanced by using a Cas9
that can be dimerized, e.g. using the FK506 binding
protein 12 (FKBP) and FKBP rapamycin binding (FRB)
domain system [15]. Alternatively, the two ends may be
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Fig. 2 Chromosomal translocations are generated at high efficiency. (a) Schematic representation of DNA breakpoints and primers used for PCR
amplification. (b) Overall efficiency of chromosomal translocations in eHAP cells. Clones were genotyped by PCR as shown in Additional file 2: Figure
S2. (c) Agarose gel analysis of PCR amplified products. Individual clones bearing the CD74-ROS1 fusion (clone 1G13) or the BCR-ABL1 reversion (clone
4 L20) were characterized by PCR from genomic DNA. Primer sequences are specified in Additional file 3: Figure S3
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both ends of the junction that one wishes to establish
[16].
While the high efficiency we observed is desired when
engineering chromosomal translocations, it may be
undesired in other instances, e.g. when engineering double
knockouts. We suspect that at least in some instances, the
simultaneous delivery of two guide RNAs will cause trans-
locations and other genomic rearrangements as unwanted
side effects. While these can easily be assessed in clonal cell
lines that proliferate almost indefinitely, they may be more
difficult to detect in scenarios where cell populations are
more heterogeneous.
We used the haploid human cell line eHAP for the
experiments presented here. In our view, this choice
offers three major advantages, all of which are based on
the fact that the cell carries a single genome copy: (i)
Genotyping is a lot more straightforward than in diploid
cells, (ii) Reversion back to wild-type configuration is
hampered because a suitable homology template is missing
and (iii) Cell lines derived contain 100 % allele burden with
regard to the chromosomal translocation. However, we
believe that this approach would be equally feasible in
diploid cells. To exemplify this, we transduced diploid
293 T cells with two gRNAs for CD74 and ROS1 and
detected both the CD74-ROS1 fusion and the reciprocal
ROS1-CD74 fusion by PCR (Additional file 4: Figure S4).
Whereas most people so far use the CRISPR technology for
research applications, the technology also offers the
potential to develop new therapies. As many translocations
represent driver events of tumorigenesis (as opposed to
passenger events), it is conceivable that CRISPR-mediated
reversion of an oncogenic fusion event may become a
therapeutic strategy in the distant future.
Conclusion
The diagnosis of cancer is increasingly based on the
characterization of the underlying genomic events. For
these diagnostic procedures, robust reference materials
that allow the standardization across laboratories are
largely missing. We envisage that cell lines generated
here and in future will be useful as a source of genomic
DNA or mRNA that can be utilized for this purpose,
alongside with DNA from an isogenic wild-type cell line.
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Fig. 3 Gene fusions are detectable at the mRNA level. (a) Left panel: Total RNA was extracted from clones 1G13 (CD74-ROS1) or 4 L20 (BCR-ABL1
reversion) and analysed for the presence of CD74-ROS1 fusion or the presence of the BCR and ABL1 by non-quantitative RT-PCR. Right panel:
schematic representation of generated cDNAs and primers used for PCR amplification. (b) Sanger sequencing of rearranged cDNA in clones 1G13
(CD74-ROS1) or 4 L20 (BCR-ABL1 reversion)
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increase the quality of diagnostic output and will thus




We used an expression plasmid in which Cas9 from
Streptococcus pyogenes was expressed from a CMV pro-
moter. Guide RNA sequences are shown in Additional
file 1: Figure S1 (gRNA3188 GGTCAAAGGGCCA
CCCTGCC, gRNA3190 GTTAAATTTAGTTGAAG
CAC, gRNA3279 TGTAGGTAGTTGTACCAATA and
gRNA3281 GACCTGTCTTTTAGACAGGC). Genome
editing in eHAP cells was performed as described
previously [13]. In brief, we transfected eHAP cells in
6 well plates using Turbofectin (Origene). Cells were
transfected with 1 μg of Cas9 expression vector and
0.8 μg of guide RNA expression vector. To enrich for
transfected cells, we cotransfected 0.2 μg of a plasmid
encoding a blasticidin resistance gene and subjected
cells to transient selection with 20 μg/ml blasticidin for
24 h. Transfected cells were expanded for limiting
dilution after 2–3 days after blasticidin selection.
Isolation of single-cell clones
Single eHAP clones were obtained by limiting dilution.
Cells were trypsinized and serially diluted to a concen-
tration of 15 cells per mL. Fifty microliters of this
suspension were seeded in each well of a 384-well
plate. Plates were imaged on day 0 and 7 after dilution
using Cell Metric™ CLD imaging system (Solentim) to
guaranty cell line clonality. Monoclonal cell lines were
expanded using Microlab STAR Line robotic system
(Hamilton Company).
Genomic DNA isolation and PCR
For the primary PCR screen, genomic DNA was
prepared using DirectPCR Lysis reagent (PeqLab)
containing Proteinase K (Sigma). Genomic DNA was
isolated from selected clones using the Gentra Pure-
gene Cell Kit (Qiagen) according to manufacturer’s
instructions. PCR was performed using GoTaq
Polymerase (Promega) according to manufacturer’s
instructions. PCR products were analysed using 1 %
TAE agarose.
RT-PCR
Total RNA was purified using RNAeasy Plus Mini Kit
(Qiagen) and cDNA was synthesized using SuperScript®
III Reverse Transcriptase (Thermo Fisher Scientific)
according to manufacturer’s instructions.
Spectral karyotyping
Spectral karyotyping was performed and analyzed by
WiCell Cytogenetics. In brief, metaphase chromosome
spreads were prepared on slides according to standard
cytogenetic procedures. These slide preparations were
then hybridized according to the DNA spectral karyo-
typing hybridization and detection protocol provided by
Applied Spectral Imaging (ASI) using the supplied SKY
probes and detection system. Images were captured and
analysed using the HiSKYV spectrum imaging system
from ASI.
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Fig. 4 Clonal cell lines bear no additional genomic alterations. eHAP
parental cells (a) or clones bearing the CD74-ROS1 fusion (clone
1G13; b) or the BCR-ABL1 reversion (clone 4 L20; c) were analysed
by spectral karyotyping
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Additional files
Additional file 1: Figure S1. DNA sequences of targeted genomic
loci and position of used gRNAs. (A) Sequences of CD74 and ROS1
targeted introns. (B) Genomic sequences of BCR-ABL1 and ABL1-BCR
rearrangements. (PPTX 202 kb)
Additional file 2: Figure S2. Original PCR screens for CD74-ROS1
translocation and BCR-ABL1 reversion (only results for 96 clones are
shown for each rearrangement). (A) PCR screen on gDNA for clones
harbouring CD74-ROS1 and ROS1-CD74 rearrangements. Asterisk indicates
positive clone. (B) PCR screen on gDNA for clones harbouring repaired BCR
and ABL1 genes. (PPTX 1609 kb)
Additional file 3: Figure S3. Primers used for gDNA and cDNA
amplification. (PPTX 38 kb)
Additional file 4: Figure S4. Generation of CD74-ROS1 fusion in
HEK293T cell line. We applied Cas9 together with two guide RNAs, targeting
the two breakpoints that we aimed to create. We genotyped pooled cells
for the presence of the CD74-ROS1 translocation with primers (Fig 1a)
spanning the newly generated junctions. (PPTX 96 kb)
Additional file 5: Figure S5. Sequences of gDNA junctions. (A) gDNA
sequence of CD74-ROS1 fusion junction in 1G13 clone. Red rectangle
indicates deletion. (B) gDNA sequence of ROS1-CD74 fusion junction in
1G13 clone. Red rectangle indicates insertion. (C) Repaired genomic
sequence of BCR gene in 4 L20 clone. (D) Repaired genomic sequences
of ABL1 gene in 4 L20 clone. (PPTX 314 kb)
Additional file 6: Figure S6. G-band staining. (A) Clone 1G13
containing CD74-ROS1 fusion. (B) Clone 4 L20 containing intact BCR
and ABL1 genes. (PPTX 271 kb)
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